Table 1.
Patient characteristics.
| Characteristic | All-data set (N = 125) | Training set (N = 85) | Test set (N = 40) |
|---|---|---|---|
| No. (%) | No. (%) | No. (%) | |
| Age (year) | |||
| Median (range) | 51 (27–74) | 52 (27–74) | 51 (28–68) |
| Gender | |||
| Men | 92 (73.6) | 63 (74.1) | 29 (72.5) |
| Women | 33 (26.4) | 22 (25.9) | 11 (27.5) |
| T-stage a | |||
| T1 | 14 (11.2) | 8 (9.4) | 6 (15.0) |
| T2 | 37 (29.6) | 26 (30.6) | 11 (27.5) |
| T3 | 46 (36.8) | 31 (36.5) | 15 (37.5) |
| T4 | 28 (22.4) | 20 (23.5) | 8 (20) |
| N-stage a | |||
| N0 | 5 (4.0) | 5 (5.9) | 0 (0.0) |
| N1 | 19 (15.2) | 16 (18.8) | 3 (7.5) |
| N2 | 78 (62.4) | 51 (60.0) | 27 (67.5) |
| N3 | 23 (18.4) | 13 (15.3) | 10 (25.0) |
| Clinical staging a | |||
| I | 1 (0.8) | 1 (1.2) | 0 (0.0) |
| II | 10 (8) | 10 (11.8) | 0 (0.0) |
| III | 70 (56) | 45 (52.9) | 25 (62.5) |
| IV | 44 (35.2) | 29 (34.1) | 15 (37.5) |
| EGFR | |||
| Yes | 19 (15.2) | 13 (15.3) | 6 (15.0) |
| No | 106 (84.8) | 72 (84.7) | 34 (85.0) |
| RIL grade | |||
| G2 | 15 | 12 | 3 |
| G3 | 85 | 58 | 27 |
| G4 | 25 | 15 | 10 |
a
According to the eighth edition of the International Union against Cancer/American Joint Committee on Cancer (UICC/AJCC) staging manual.